Cytori Therapeutics (NASDAQ:CYTX) issued its earnings results on Thursday. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.02), Bloomberg Earnings reports. Cytori Therapeutics had a negative return on equity of 228.21% and a negative net margin of 367.33%. The firm had revenue of $1.50 million during the quarter, compared to analysts’ expectations of $2.00 million.
Shares of Cytori Therapeutics (NASDAQ CYTX) traded down $0.00 during midday trading on Friday, hitting $0.32. The company had a trading volume of 1,430,000 shares, compared to its average volume of 1,240,000. The stock has a market cap of $11.06, a PE ratio of -0.36 and a beta of 3.49. Cytori Therapeutics has a 1 year low of $0.22 and a 1 year high of $2.08.
In related news, major shareholder Bank Sa Swissquote sold 100,000 shares of the company’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $0.38, for a total transaction of $38,000.00. Following the completion of the sale, the insider now directly owns 5,496,655 shares in the company, valued at approximately $2,088,728.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Ag Postfinance sold 286,982 shares of the company’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $0.31, for a total value of $88,964.42. Following the sale, the insider now owns 5,118,627 shares of the company’s stock, valued at $1,586,774.37. The disclosure for this sale can be found here. Insiders have sold a total of 695,767 shares of company stock valued at $231,951 over the last 90 days. 1.90% of the stock is currently owned by company insiders.
CYTX has been the subject of several research reports. ValuEngine upgraded Cytori Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Zacks Investment Research cut Cytori Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, February 13th. Maxim Group set a $4.00 target price on Cytori Therapeutics and gave the stock a “buy” rating in a report on Tuesday, February 13th. B. Riley upgraded Cytori Therapeutics from a “neutral” rating to a “buy” rating in a report on Friday. Finally, Laidlaw reiterated a “buy” rating and issued a $1.65 target price on shares of Cytori Therapeutics in a report on Thursday, February 22nd. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the company. Cytori Therapeutics currently has an average rating of “Hold” and an average target price of $1.80.
COPYRIGHT VIOLATION NOTICE: “Cytori Therapeutics (CYTX) Posts Quarterly Earnings Results” was first published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3254010/cytori-therapeutics-cytx-posts-quarterly-earnings-results.html.
About Cytori Therapeutics
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.